Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04488003 · ClinicalTrials.gov registry record · Phase 2
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
A Phase 2 study, sponsored by BioMed Valley Discoveries.
- Terminated
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT04488003: Clinical Trial Phase 2 study, sponsored by BioMed Valley Discoveries.
NCT04488003 is a Phase 2 study that was terminated before completion, run by BioMed Valley Discoveries. The registered enrollment target is 104 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04488003, a Phase 2 study, was terminated before completion, sponsored by BioMed Valley Discoveries.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional development is warranted.
Primary Outcome
ORR will be defined as the percentage of patients achieving a Best Overall Response (BOR) of confirmed Complete Response (CR) and/or Partial Response (PR). Patients will be evaluated at baseline \& at periodic follow-up visits through the time their participation in the study is complete.The best responses will occur at different time points for each patient.
Interventions
- DRUG Ulixertinib
- DRUG Physician's Choice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2023-05-23 |
| Phase | Phase 2 |
Why NCT04488003 stopped before completion
NCT04488003 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 2 interventions - of which Ulixertinib is the first listed.
NCT04488003 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04488003 about?
NCT04488003 is a clinical study titled "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations". This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early c...
What is the current status of trial NCT04488003?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2021-01-07. Estimated completion is 2023-05-23.
What interventions are being tested in trial NCT04488003?
The interventions under investigation include: Ulixertinib (DRUG), Physician's Choice (DRUG).
Who is sponsoring clinical trial NCT04488003?
This trial is sponsored by BioMed Valley Discoveries, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04488003's enrollment target sits among peer trials
104 660th of 2000 higher than 1,337 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI